Transcatheter aortic valve replacement: Protect the kidneys to protect the patient

• Transcatheter aortic valve replacement (TAVR) seems superior to surgical aortic valve replacement (SAVR) for intermediate‐term outcomes in patients with aortic stenosis and moderate to severe chronic kidney disease (CKD).
• Intermediate‐term mortality and the major adverse cardiac and renal event increase if the renal function worsens soon after TAVR or SAVR.
• Patient's demographic profile, comorbid conditions, and procedural characteristics influence the clinical outcomes emphasizing the need for careful risk assessment in deciding TAVR versus SAVR in CKD patient.